siRNA Pools Targeting Immunoglobulin Light Chains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for diseases related to immunoglobulins and immunoglobulin-producing plasma cells, such as clonal plasma cell dyscrasias and autoimmune diseases, are often ineffective and come with significant side effects, and existing treatments for autoimmune disorders are not always successful in managing symptoms.
Innovation Solution
The development of nucleic acid-based compounds, specifically siRNA pools that target immunoglobulin light chain production, allowing for the universal inhibition of kappa or lambda light chain production without prior knowledge of the specific sequence, leading to plasma cell death and potential therapeutic benefits for plasma cell-mediated or immune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies (steroids, chemotherapy agents, proteasome inhibitors) are used to treat plasma cell dyscrasias and autoimmune diseases, then some therapeutic effect is achieved, but serious side effects occur and diseases remain incurable
Solution Approach 1:
The patent replaces traditional chemical-based therapies (steroids, chemotherapy agents like melphalan and adriamycin, proteasome inhibitors) with a nucleic acid-based mechanism (siRNA) that utilizes the cell's own RNA interference machinery to achieve therapeutic effects. This substitution fundamentally changes the mode of action from external chemical interference to internal gene silencing, thereby achieving disease targeting with reduced side effects
2Reliability
If universal siRNA pools targeting immunoglobulin light chain production are administered, then plasma cell death is induced and immunoglobulin production is inhibited, but the specific sequence of the particular immunoglobulin must be unknown
Solution Approach 1:
The patent employs universal siRNA pools that can target and inhibit production of immunoglobulin light chains (both kappa and lambda types) without requiring knowledge of the specific sequence of the particular immunoglobulin produced by the plasma cells. This universality is achieved by designing siRNA pools that cover conserved regions of immunoglobulin genes, allowing a single therapeutic composition to be effective against diverse plasma cell dyscrasias regardless of the specific clonal immunoglobulin produced
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siRNA compounds effectively reduce immunoglobulin light chain production, halt the production of intact antibodies, and induce apoptosis in plasma cells, providing a potential therapeutic approach for clonal plasma cell dyscrasias and autoimmune disorders with reduced side effects.
Implementation Method 1
nucleic acid based compounds for targeting immunoglobulins... specifically siRNA pools that target immunoglobulin light chain production... The siRNA compounds effectively reduce immunoglobulin light chain production
Data Source
AI summary
The present invention relates to compositions and methods for targeting immunoglobulins and immunoglobulin-producing plasma cells. In particular, the present invention provides nucleic acid based compounds for targeting immunoglobulins for research, screening, and therapeutic applications.